4 marks Pathophysiology 4. Drug name 1 mark Drug Question 1 A 67-year-

(4 marks) Pathophysiology 4. Drug name (1 mark) Drug Question 1 A 67-year-old man presents with complaints of weight loss, fatigue and altered bowel habits for the past 6 months. A stool sample is positive for occult blood. Peripheral blood smear reveals presence of microcytic, hypochromic anaemia. On colonoscopy, a polypoid, ulcerative lesion is seen projecting into the ascending colon. Partial colectomy followed by histopathologic examination reveals a well differentiated adenocarcinoma.Patient is started on haematinics and anticancer therapy combination of 5-fluorouracil and oxaliplatin. 1. Explain the pathophysiology of the following symptoms seen in this patient. Presentation Altered bowel habits Fatigue 2. Describe the morphologic features expected to be seen in microscopic examination of the resected tumour of this patient. (2 marks) 3. State ONE (1) haematinic which is suitable for this patient and its rationale for prescription. (2 marks) Rationale for prescription (1 mark) 5. Describe the mechanism of action for ONE (1) anticancer drug stated above and TWO (2) respective side effects. (2 marks) Mechanism of action (1 mark) Side effects (1 mark) [10 Mark] 1 point is 0.5 mark

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have sufficient information from the textbooks to provide a thorough, well-structured answer to all parts of this question.

Question 1 - Full Model Answer (10 marks)

Part 1: Pathophysiology of Symptoms (4 marks)

Altered Bowel Habits

The adenocarcinoma is located in the ascending (right) colon. As the tumour grows, it progressively narrows the colonic lumen, partially obstructing faecal transit. This causes a change in stool calibre, constipation, or paradoxical overflow diarrhoea. The ulcerative surface of the tumour causes mucosal irritation, triggering increased colonic peristalsis and secretion of mucus, leading to alternating loose stools and constipation. Partial luminal obstruction and abnormal colonic motility together produce the clinical pattern of altered bowel habits.

Fatigue

The fatigue arises secondary to chronic blood loss anaemia. The ulcerative tumour on the surface of the ascending colon continuously bleeds at a slow, occult rate - this is evidenced by the positive faecal occult blood test. Sustained blood loss depletes the body's iron stores, resulting in iron-deficiency anaemia (seen as microcytic, hypochromic red cells on the peripheral smear). Reduced haemoglobin means decreased oxygen-carrying capacity of the blood, leading to tissue hypoxia, decreased oxidative metabolism in muscles, and the clinical manifestation of persistent fatigue and exercise intolerance. The weight loss itself contributes via cytokine-mediated catabolism (TNF-α, IL-6 from the tumour microenvironment), which further impairs energy production.

Part 2: Microscopic Morphologic Features of Well-Differentiated Colonic Adenocarcinoma (2 marks)

On histopathological examination, the following features are expected:

Glandular architecture - The tumour is composed of well-formed neoplastic glands lined by columnar cells with stratified, hyperchromatic nuclei. Being "well differentiated," the glands closely resemble normal colonic crypts (high glandular differentiation grade 1).
Nuclear atypia - Enlarged, pleomorphic, hyperchromatic nuclei with prominent nucleoli and increased nuclear:cytoplasmic ratio.
Increased mitotic figures - Abnormal mitoses reflecting rapid tumour cell proliferation.
Mucin secretion - Intracellular and extracellular mucin pools may be present (goblet cell differentiation).
Desmoplastic stroma - The neoplastic glands invade through the submucosa and muscularis propria, inciting a fibrous (desmoplastic) stromal reaction.
Loss of normal polarity - Nuclei pile up toward the luminal surface, losing the normal basal orientation.

Part 3: Haematinic and Rationale (2 marks)

Drug Name: Ferrous sulfate (Oral Iron)

Rationale: This patient has iron-deficiency anaemia caused by chronic occult blood loss from the ulcerating colonic adenocarcinoma. The peripheral smear shows microcytic, hypochromic red cells, which is the characteristic pattern of iron deficiency. Iron is required for haemoglobin synthesis - specifically for haem biosynthesis (iron is incorporated into protoporphyrin IX to form haem). Depletion of iron stores reduces haemoglobin production, resulting in small, pale red cells. Supplementing with oral ferrous iron (ferrous sulfate 200 mg three times daily) replenishes depleted iron stores, restores effective erythropoiesis in the bone marrow, and corrects the haemoglobin deficit - thus reversing fatigue and improving the patient's functional status during chemotherapy.

(Note: Vitamin B12 or folate would be inappropriate here because the anaemia is microcytic/hypochromic - B12/folate deficiency causes macrocytic anaemia.)

Part 4: Drug Name (1 mark)

5-Fluorouracil (5-FU)

Part 5: Mechanism of Action and Side Effects of 5-FU (2 marks)

Mechanism of Action:

5-Fluorouracil (5-FU) is a pyrimidine antimetabolite. It is metabolically converted intracellularly to its active form, 5-fluoro-2'-deoxyuridine monophosphate (5-FdUMP). 5-FdUMP forms a stable ternary complex with thymidylate synthase (TS) and the folate cofactor 5,10-methylenetetrahydrofolate (5,10-CH₂-THF), irreversibly inhibiting thymidylate synthase (a "suicide inhibitor"). This blocks the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), thereby depleting the cellular pool of dTMP - an essential precursor for DNA synthesis. Without dTMP, DNA replication halts and the cell undergoes apoptosis. 5-FU is also incorporated directly into RNA, disrupting RNA processing and protein synthesis. Rapidly dividing tumour cells are preferentially affected.

(Source: Biochemistry, 8th ed. Lippincott Illustrated Reviews, p. 853; Dermatology 2-Volume Set 5e)

Side Effects (TWO):

Myelosuppression - Suppression of rapidly dividing bone marrow cells leads to leucopenia, thrombocytopenia, and anaemia, increasing the risk of infection and bleeding.
Mucositis / Stomatitis - Destruction of the rapidly proliferating gastrointestinal mucosal epithelium causes painful oral ulcers (mucositis), diarrhoea, and nausea/vomiting.

(Additional notable side effects include palmar-plantar erythrodysesthesia "hand-foot syndrome" and cardiotoxicity, but the two above are the most classic.)

Summary Table

Question	Answer
Altered bowel habits	Tumour mass partially obstructs lumen + ulceration irritates mucosa → changed motility
Fatigue	Chronic occult blood loss → iron deficiency anaemia → reduced O₂ delivery → tissue hypoxia
Microscopic features	Neoplastic well-formed glands, nuclear atypia, mucin, desmoplastic stroma, invasion
Haematinic	Ferrous sulfate (oral iron) - corrects iron deficiency from chronic blood loss
Drug name (Q4)	5-Fluorouracil (5-FU)
MOA	Suicide inhibition of thymidylate synthase → blocks dTMP synthesis → DNA replication failure
Side effects	Myelosuppression; Mucositis/stomatitis

Question 2 An 8-year-old boy is brought to the Emergency Department following two episodes of generalised tonic-clonic seizures. He had history of high-grade fever headache and vomiting for the past two days. On examination, he is drowsy, temperature is 40C, pulse rate 110 beats per min, blood pressure 100/70 mm Hc and respiratory rate is 18 breaths per min. Lumbar puncture is performed, and the cerebrospinal fluid (CSF) is sent to the laboratory for investigation. He is admitted in Paediatric ICU and is administered with intravenous lorazepam to control the seizures. The result of cerebrospinal fluid examination is as follows: Test Appearance Total WBC count Neutrophil count Glucose Protein Gram stain Reference range Clear 0-5 cells/ mm3 0-5 cells/mm3 40-70 mg/dL 15-50 mg/dl No organism He is diagnosed with meningitis and started on treatment with intravenous benzylpenicillin. He is diagnosed with meningitis and started on treatment with intravenous benzylpenicillin. 1. State the most likely causative organism in this case. 2. State the reason for the following findings in the CSF examination of this patient. (2 marks) Findings Low glucose level High protein level Result Cloudy 1200 cells/ mm3 1050 cells/ mm3 28 mg/dL 350 mg/dl Gram-negative diplococci z chhrike ch (1 mark) backnn conjune tr jttoft Reason (1 mark each) - incvease i arhlody -backna burst - vin replicate 3. State THREE (3) virulence factors of the causative organism answered in Q1 and briefly describe their respective role in the pathogenesis of the above infection. Virulence Factor (0.5 mark) (3 marks) Role in the Pathogenesis (0.5 mark) 4. State TWO (2) nervous system complications of this condition. 5. Explain the mechanism of action of lorazepam. 6. State the mode of action of benzylpenicillin. (1 mark) (2 marks) (1 mark)

Reading File

Finding Sources

Reading File

Finding Sources

I now have all the textbook evidence needed. Here is the complete model answer:

Question 2 - Full Model Answer (10 marks)

Part 1: Most Likely Causative Organism (1 mark)

Neisseria meningitidis (Meningococcus)

Key evidence from the CSF:

Gram-negative diplococci on Gram stain - the classic morphology of N. meningitidis
Neutrophilic pleocytosis (1050/1200 cells = ~87% neutrophils) - typical of bacterial meningitis
Cloudy CSF, markedly low glucose (28 mg/dL), markedly elevated protein (350 mg/dL)
Age group: N. meningitidis is the most common cause of bacterial meningitis in children and young adults (5 months - 20 years)

Part 2: Reasons for CSF Findings (2 marks)

Low CSF Glucose (28 mg/dL; normal 40-70 mg/dL)

Bacteria (particularly N. meningitidis) actively consume glucose as their primary energy substrate, directly depleting glucose within the CSF. Additionally, the intense inflammatory response in the subarachnoid space causes dysfunction of the glucose transporters (GLUT1) on the blood-brain barrier and choroid plexus, impairing glucose transport from blood into CSF. The activated neutrophils and macrophages also utilise large amounts of glucose through glycolysis. The net result is a dramatic fall in CSF glucose, typically below 40 mg/dL (or CSF:serum glucose ratio < 0.4).

High CSF Protein (350 mg/dL; normal 15-50 mg/dL)

Bacterial infection and the release of bacterial products (endotoxin/lipooligosaccharide) trigger an intense inflammatory cascade in the subarachnoid space. Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) disrupt the tight junctions of the blood-brain barrier, dramatically increasing its permeability. This allows large plasma proteins (albumin, immunoglobulins) to leak from blood vessels into the CSF. Dead and lysed neutrophils also release their intracellular proteins locally. The result is a markedly elevated CSF protein, often >100 mg/dL in bacterial meningitis.

Part 3: THREE Virulence Factors of Neisseria meningitidis and Their Role in Pathogenesis (3 marks)

Virulence Factor	Role in Pathogenesis
1. Polysaccharide Capsule	The thick polysaccharide capsule (serogroups A, B, C, W, Y) is the most important virulence factor. It inhibits phagocytosis by neutrophils and macrophages by preventing opsonisation. It also resists complement-mediated bacteriolysis by blocking deposition of the membrane attack complex (C5b-9) on the bacterial outer membrane. This allows N. meningitidis to survive in the bloodstream and establish bacteraemia before invading the CSF.
2. Pili (Fimbriae)	Type IV pili mediate initial attachment of the organism to nasopharyngeal epithelial cells and to the endothelium of brain microvessels. They enable the bacteria to colonise the nasopharynx (first step), resist ciliary clearance, and subsequently cross the blood-brain barrier by transcytosis - allowing the organism to enter the subarachnoid space and establish meningitis.
3. IgA1 Protease	N. meningitidis secretes IgA1 protease, which cleaves secretory IgA1 at the hinge region. Since IgA is the primary mucosal immunoglobulin of the nasopharynx, destroying it allows the organism to evade the first line of mucosal immunity, persist at the nasopharyngeal mucosa, and establish a portal of entry into the bloodstream.

(Additional accepted factors: Lipooligosaccharide/LOS [endotoxin that triggers cytokine storm, DIC, and septic shock]; Outer membrane proteins [aid immune evasion and cell invasion].)

Part 4: TWO Nervous System Complications of Bacterial Meningitis (1 mark)

Sensorineural hearing loss (deafness) - caused by inflammation and exudate spreading to the cochlea and auditory nerve via the internal auditory canal; it is the most common neurological sequela, affecting up to 30% of survivors.
Hydrocephalus - pus and inflammatory exudate in the subarachnoid space obstruct CSF resorption at the arachnoid granulations (communicating hydrocephalus) or block the foramina of Luschka/Magendie (obstructive hydrocephalus), leading to raised intracranial pressure.

(Other acceptable answers: cerebral venous sinus thrombosis, brain abscess, subdural empyema, cerebral infarction, seizure disorder, cognitive impairment.)

Part 5: Mechanism of Action of Lorazepam (2 marks)

Lorazepam is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor.

The GABA-A receptor is a ligand-gated chloride ion channel composed of five subunits (typically 2α, 2β, 1γ). GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter of the CNS. When GABA binds to its orthosteric sites (between α and β subunits), it opens the chloride channel, allowing Cl⁻ ions to flow into the neuron, hyperpolarising the membrane and inhibiting neuronal firing.

Lorazepam binds to a distinct allosteric site located at the interface between the α and γ subunits. It does not directly open the channel on its own. However, when GABA is also present, lorazepam enhances GABA binding affinity and increases the frequency of chloride channel opening (compared to barbiturates, which increase the duration). This potentiates Cl⁻ influx, causing greater neuronal hyperpolarisation, widespread CNS inhibition, and suppression of the abnormal, synchronised neuronal discharges responsible for seizures.

(Source: Stahl's Essential Psychopharmacology; Morgan & Mikhail's Clinical Anesthesiology, 7e)

Part 6: Mode of Action of Benzylpenicillin (Penicillin G) (1 mark)

Benzylpenicillin is a beta-lactam antibiotic that acts by inhibiting bacterial cell wall synthesis.

Specifically, benzylpenicillin irreversibly binds to Penicillin-Binding Proteins (PBPs) - enzymes (transpeptidases and carboxypeptidases) located on the inner surface of the bacterial cell membrane. These enzymes are responsible for catalysing the final cross-linking (transpeptidation) step of peptidoglycan biosynthesis, forming the rigid cell wall. The beta-lactam ring of penicillin structurally mimics the D-Ala-D-Ala terminus of the peptidoglycan precursor and covalently acylates the active site of PBPs, permanently inactivating them. This blocks peptidoglycan cross-linking, weakening the cell wall. The organism cannot withstand osmotic pressure and undergoes cell lysis and death. Benzylpenicillin is therefore bactericidal, and is effective against N. meningitidis because it is a penicillin-sensitive Gram-negative organism.

Summary Table

Part	Key Answer
Q1: Organism	Neisseria meningitidis (Gram-negative diplococci)
Q2: Low glucose	Bacterial consumption + impaired BBB glucose transport
Q2: High protein	BBB disruption by inflammation → plasma protein leakage
Q3: Virulence factor 1	Polysaccharide capsule - anti-phagocytic, complement evasion
Q3: Virulence factor 2	Pili - mucosal adhesion and BBB invasion
Q3: Virulence factor 3	IgA1 protease - destroys mucosal IgA, enables nasopharyngeal colonisation
Q4: Complications	Sensorineural deafness; Hydrocephalus
Q5: Lorazepam MOA	Positive allosteric modulator of GABA-A receptor → increases Cl⁻ channel opening frequency → neuronal hyperpolarisation → seizure suppression
Q6: Benzylpenicillin MOA	Binds PBPs → blocks transpeptidation of peptidoglycan → cell wall lysis → bactericidal

1. A 40-year-old man comes to the Emergency Department with fever, alternating constipation, and diarrhea for one week. On examination, his temperature was 40oC, pulse rate 80/min and had fair hydration. There is hepatosplenomegaly and rose spots on his back. Based on laboratory investigation, diagnosis of typhoid fever was made. The patient was started treatment with Ceftriaxone intravenously. i. ii. iii. iv. Describe the pathogenesis of this condition. (4m) State THREE (3) microbiological laboratory tests and their findings used to confirm the diagnosis. Test (0.5 marks each) Findings (0.5 marks each) State TWO (2) complications in this condition. (1m) Describe the MOA of drug given to this patient. (2m) 1 point 0.5 mark

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the information needed from authoritative textbooks. Here is the complete model answer:

Typhoid Fever - Full Model Answer (10 marks)

Part (i): Pathogenesis of Typhoid Fever (4 marks)

Step 1 - Ingestion and Colonisation Salmonella typhi is transmitted via the fecal-oral route through contaminated food or water. After ingestion, the organism must survive the acidic gastric environment. It then reaches the small intestine (terminal ileum) where it specifically targets and invades the M cells (microfold cells) overlying the Peyer's patches of the lymphoid follicles.

Step 2 - Intracellular Invasion and Local Spread Using its virulence genes (Salmonella Pathogenicity Islands - SPI-1 and SPI-2), S. typhi injects effector proteins into M cells via a type III secretion system. These proteins activate host cell Rho GTPases, triggering actin rearrangement and bacterial uptake into phagosomes. Unlike non-typhoidal salmonella, S. typhi is uniquely able to survive and replicate within macrophages and mononuclear phagocytes in the underlying lymphoid tissue - this is the key step that distinguishes typhoid fever. This causes the Peyer's patches to enlarge dramatically into plateau-like elevations, with mucosal shedding creating oval ulcers oriented along the long axis of the ileum.

Step 3 - Primary Bacteraemia (End of Week 1) The intracellular organisms are transported within macrophages via the mesenteric lymphatics to the mesenteric lymph nodes, where they multiply further. They then drain into the thoracic duct and enter the systemic circulation, producing a primary (transient) bacteraemia. This is when blood cultures are most positive (60-90% yield). The patient develops the classic features of sustained high fever, headache, relative bradycardia (Faget sign), and hepatosplenomegaly due to hyperplasia of the reticuloendothelial system.

Step 4 - Seeding of the Gallbladder and Secondary Bacteraemia (Week 2-3) The bacteria seed the liver and gallbladder via the portal circulation. The gallbladder acts as a reservoir, and organisms re-enter the gut via bile, causing massive re-infection of the Peyer's patches and a secondary (sustained) bacteraemia. This systemic dissemination explains the characteristic rose spots - small erythematous maculopapular lesions on the trunk caused by bacterial emboli in the dermal capillaries. Typhoid nodules (small foci of macrophage aggregates) appear in the liver, spleen, and bone marrow. The spleen's red pulp expands due to phagocyte hyperplasia, causing the splenomegaly seen on examination.

Step 5 - Complications (Week 3-4) The heavily ulcerated Peyer's patches may erode through the bowel wall, causing intestinal haemorrhage or perforation - the most feared complications. The organism may also disseminate to cause pneumonia, meningitis, endocarditis, or osteomyelitis.

(Sources: Robbins & Kumar Basic Pathology; Sleisenger & Fordtran's GI and Liver Disease)

Part (ii): THREE Microbiological Laboratory Tests and Findings (3 marks)

Test (0.5 mark each)	Findings (0.5 mark each)
1. Blood Culture	Isolation of Salmonella typhi - the primary diagnostic test. Positive in 60-80% of patients during the febrile phase (Week 1). Bile-based media (e.g. tryptose phosphate broth) or automated BACTEC systems are used.
2. Widal Test (Tube Agglutination)	Detects rising serum titres of agglutinating antibodies against S. typhi somatic O antigen (appear Day 6-8) and flagellar H antigen (appear Day 10-12). A 4-fold rise in convalescent titre (≥1:160 for O, ≥1:160 for H) is considered diagnostic. Note: sensitivity and specificity are moderate; cross-reactions with other Salmonella species can give false positives.
3. Bone Marrow Culture	Considered the gold standard - positive in >90% of cases even in patients who have already received antibiotics, because intracellular organisms persist within macrophages. A sample is aspirated from the posterior iliac crest and cultured on blood or MacConkey agar. S. typhi colonies are non-lactose fermenting, H₂S-producing, and agglutinate with specific anti-sera.

(Additional accepted test: Stool/urine culture - stool cultures positive in Weeks 2-3; urine cultures positive in ~25% by Week 3)

Part (iii): TWO Complications of Typhoid Fever (1 mark)

Intestinal Perforation - Erosion of ulcerated Peyer's patches through the full thickness of the ileal wall, causing peritonitis. Occurs most commonly in Week 3. Presents with acute abdomen, rebound tenderness, and radiological evidence of free air under the diaphragm. Mortality is high without surgical intervention.
Intestinal Haemorrhage - Ulceration erodes submucosal blood vessels in the ileum, causing significant lower GI bleeding (fresh blood or melaena). Bleeding often precedes perforation in the same patient. Before antibiotics, haemorrhage occurred in up to 20% of cases.

(Other accepted complications: typhoid encephalopathy/toxic state, myocarditis, pneumonia, cholecystitis, chronic carrier state, osteomyelitis)

Part (iv): Mechanism of Action of Ceftriaxone (2 marks)

Ceftriaxone is a third-generation cephalosporin and, like all beta-lactam antibiotics, it acts by inhibiting bacterial cell wall (peptidoglycan) synthesis.

Mechanism:

The bacterial cell wall is composed of a rigid peptidoglycan (murein) layer that maintains structural integrity against osmotic pressure. Peptidoglycan consists of repeating disaccharide units (N-acetylmuramic acid and N-acetylglucosamine) cross-linked by short peptide bridges. The final and critical step in cell wall assembly is transpeptidation - the cross-linking of adjacent peptide chains - which is catalysed by enzymes called Penicillin-Binding Proteins (PBPs), specifically transpeptidases.

Ceftriaxone contains a beta-lactam ring that structurally mimics the D-Ala-D-Ala terminus of the peptidoglycan pentapeptide precursor (the natural substrate of PBPs). Ceftriaxone covalently binds to and irreversibly acylates the active site serine of PBPs, permanently inactivating them. This prevents transpeptidation and cross-linking of the peptidoglycan chains, so the cell wall cannot be properly assembled or maintained.

The resulting structurally defective cell wall cannot withstand the osmotic pressure differential between the bacterial cytoplasm and the external environment. This causes the bacterium to take up water, swell, and undergo cell lysis and death - making ceftriaxone bactericidal.

Additionally, inhibition of cell wall synthesis triggers the release of bacterial autolysins (murein hydrolases), which further degrade the existing peptidoglycan, accelerating bacterial lysis.

Ceftriaxone has a broad spectrum of activity against Gram-negative organisms, including S. typhi, due to its ability to penetrate the outer membrane and its high affinity for the PBPs of Gram-negative bacteria. Its long half-life (~8 hours) makes once-daily dosing possible.

(Sources: Fitzpatrick's Dermatology; Jawetz Melnick & Adelberg's Medical Microbiology 28e; Katzung's Basic and Clinical Pharmacology 16e)

Summary Table

Part	Key Answer
Pathogenesis	Ingestion → M cell invasion (Peyer's patches) → intramacrophage survival → mesenteric lymph nodes → primary bacteraemia → gallbladder seeding → secondary bacteraemia → rose spots, hepatosplenomegaly → ulcer complications
Lab Test 1	Blood culture - S. typhi isolated (60-80% positive, Week 1)
Lab Test 2	Widal test - rising O and H agglutinin titres (≥1:160 or 4-fold rise)
Lab Test 3	Bone marrow culture - gold standard, >90% positive even post-antibiotics
Complications	Intestinal perforation; Intestinal haemorrhage
Ceftriaxone MOA	Beta-lactam binds PBPs (transpeptidases) → blocks peptidoglycan cross-linking → cell wall defect → osmotic lysis → bactericidal

2. A 52-year-old woman presents with painless lumps in her right breast of 2 months duration. Her mother had history of breast cancer. On examination, her right breast is edematous with peau’d orange appearance and there is a 3X2 cm lump located in the outer upper quadrant of breast. The lump is non-tender, hard and fixed to breast. There is enlarged right axillary lymph node. Biopsy is done. Diagnosis of invasive ductal carcinoma grade 2 is made. Immunohistochemistry studies showed Estrogen Receptor (ER) – positive, Progesterone Receptor (PR) – positive and Human epidermal growth factor receptor 2 (HER-2) is negative. Patient is prescribed with a conventional, long term, oral anticancer drug with Tamoxifen. i. ii. iii. iv. Briefly explain the pathophysiology of patient’s symptoms below. (1m) Clinical presentation Edematous peau’d orange Pathophysiology Enlarged lymph node Fixation of lump Relate immunohistochemical studies to treatment and its significance in prognosis. (1.5m) Name the genetic that is associated with familial breast cancer and briefly explain its role. (1.5m) Describe the MOA of Tamoxifen and 4 adverse effects. MOA 1 mark ADVERSE EFFECTS 0.5 marks each

Finding Sources

Reading File

I now have comprehensive, textbook-verified content for every part of this question. Here is the complete model answer:

Invasive Ductal Carcinoma - Full Model Answer (10 marks)

Part (i): Pathophysiology of Clinical Presentations (1 mark - 3 presentations)

Oedematous Peau d'Orange Appearance

As the invasive ductal carcinoma grows, tumour cells invade and block the dermal lymphatic channels of the breast skin. This obstruction of lymphatic drainage causes localised lymphoedema of the overlying skin, making it swollen and thickened. The skin develops a characteristic dimpled texture resembling orange peel - "peau d'orange" - because the skin is tethered at the openings of the hair follicles and sweat gland ducts (which are anchored to the underlying dermis by Cooper's ligaments), while the surrounding oedematous skin puffs up around them. This appearance is the hallmark of inflammatory breast carcinoma or advanced local invasion of lymphatics.

Enlarged Right Axillary Lymph Node

The right upper outer quadrant tumour drains primarily to the ipsilateral axillary lymph nodes (specifically the anterior/pectoral group). As tumour cells invade lymphatic vessels, they travel via lymphatic channels to the regional axillary lymph nodes, where they lodge, proliferate, and replace normal lymphoid tissue. This tumour cell infiltration causes the node to enlarge. The node is typically hard, non-tender, and may be matted (fixed together) due to extranodal extension. Enlarged axillary nodes confirm regional (N1) metastatic spread and are a major negative prognostic indicator.

Fixation of Lump to Breast

In early breast carcinomas, lumps may be mobile. However, in invasive ductal carcinoma, the tumour invades beyond the ductal basement membrane into the surrounding stromal tissue, triggering a dense desmoplastic (fibrotic) reaction - a proliferation of reactive fibrous stroma around the tumour. This fibrosis anchors and tethers the tumour to the surrounding breast parenchyma, chest wall fascia, or overlying skin. Additionally, tumour invasion of Cooper's ligaments (fibrous suspensory ligaments of the breast) causes them to shorten and retract, fixing the lump firmly in place. This fixation indicates locally advanced disease.

Part (ii): IHC Studies - Relation to Treatment and Significance for Prognosis (1.5 marks)

ER-Positive / PR-Positive:

The presence of oestrogen receptors (ER) and progesterone receptors (PR) on tumour cells indicates that the tumour's growth is driven by oestrogen signalling. This is the most favourable hormonal subtype ("luminal A-like").

Treatment implication: This patient is an ideal candidate for endocrine (hormonal) therapy. Since she is ER+/PR+, Tamoxifen (a selective oestrogen receptor modulator) is prescribed as the primary long-term anticancer treatment. It competitively blocks oestrogen from binding to ERs in the breast, starving the tumour of its growth signal. Tamoxifen is used in pre-menopausal women; postmenopausal women may use aromatase inhibitors instead.
Prognostic significance: ER+/PR+ tumours have a favourable prognosis - they tend to be lower grade, less aggressive, have a better response to therapy, and a higher 5-year survival rate compared to ER-negative tumours. PR positivity additionally indicates a functional ER signalling pathway and predicts a better response to anti-oestrogen therapy.

HER-2 Negative:

HER-2 (Human Epidermal Growth Factor Receptor-2) is a transmembrane tyrosine kinase receptor. HER-2 negativity means there is no gene amplification or overexpression of this receptor.

Treatment implication: Since HER-2 is negative, HER-2 targeted therapies such as Trastuzumab (Herceptin) are not indicated - they would provide no benefit and are not prescribed.
Prognostic significance: HER-2 negative status is associated with a better prognosis than HER-2 positive disease. HER-2 overexpression is linked to aggressive tumour behaviour, rapid proliferation, early metastasis, and shorter disease-free survival. Its absence in this patient is a favourable prognostic marker.

Overall classification: This patient has a Luminal A (ER+/PR+/HER2-) subtype - the most common and the most favourable subtype of breast cancer in terms of prognosis and treatment response.

Part (iii): Genetic Association with Familial Breast Cancer and Its Role (1.5 marks)

Gene: BRCA1 and BRCA2 (Breast Cancer susceptibility genes 1 and 2)

Given this patient's family history of breast cancer in her mother, the most relevant associated genes are BRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12.3).

BRCA1 mutations confer a 50-85% lifetime risk of developing breast cancer and up to 40% risk of ovarian cancer.
BRCA2 mutations confer a 40-60% lifetime risk of breast cancer and 20% risk of ovarian cancer. BRCA2 is also associated with pancreatic, prostate, and male breast cancers.
Together, BRCA1 and BRCA2 mutations account for 20-25% of hereditary breast cancer cases.

Role in pathogenesis:

BRCA1 and BRCA2 function as tumour suppressor genes (TSGs) - they are essential for maintaining genomic integrity through DNA double-strand break repair (specifically the high-fidelity homologous recombination pathway). The BRCA proteins recruit and coordinate the repair machinery (including RAD51) to fix double-strand DNA breaks accurately before cell division.

Under the "two-hit hypothesis", an individual inherits one mutant (non-functional) BRCA allele in every cell (germline mutation). When the second, normal allele undergoes a somatic "second hit" mutation in a breast epithelial cell, both copies are inactivated. Without functional BRCA protein, the cell loses its ability to repair DNA double-strand breaks by homologous recombination, leading to chromosomal instability, accumulation of mutations in oncogenes and other TSGs, and uncontrolled cell proliferation - ultimately leading to cancer.

BRCA1-associated tumours tend to be high grade, triple-negative (ER-/PR-/HER2-), and carry a poorer prognosis. BRCA2-associated tumours may be ER-positive (as in some cases). Germline BRCA testing is recommended for all patients with a strong family history.

(Sources: Bailey & Love's Short Practice of Surgery 28e; Henry's Clinical Diagnosis and Management by Laboratory Methods; Sabiston Textbook of Surgery)

Part (iv): Mechanism of Action of Tamoxifen and 4 Adverse Effects (2 marks)

Mechanism of Action (1 mark):

Tamoxifen is a Selective Oestrogen Receptor Modulator (SERM). It acts as a competitive antagonist of oestrogen receptors specifically in breast tissue.

In oestrogen receptor-positive (ER+) breast cancer cells, oestrogen normally binds to the oestrogen receptor (ER-α), causing receptor dimerisation, nuclear translocation, and binding to oestrogen response elements (EREs) on DNA. This drives transcription of genes promoting cell proliferation (e.g., cyclin D1, c-Myc), cell survival, and tumour growth.

Tamoxifen and its active metabolites (particularly endoxifen) compete with oestrogen for binding to the oestrogen receptor's ligand-binding domain. Once bound, the tamoxifen-ER complex adopts a different conformational shape compared to the oestrogen-ER complex - it recruits co-repressors instead of co-activators, blocking transcription of oestrogen-responsive growth-promoting genes. This inhibits oestrogen-induced breast cancer cell proliferation and induces cell cycle arrest and apoptosis.

Importantly, tamoxifen acts as an agonist (not an antagonist) in other tissues such as bone (maintains bone density) and the endometrium (stimulates endometrial growth - a source of adverse effects).

(Source: Lippincott Illustrated Reviews: Pharmacology)

Adverse Effects (0.5 marks each - 4 required):

#	Adverse Effect	Explanation
1	Hot flushes	Due to reduced oestrogenic activity in the hypothalamus - disrupts thermoregulatory signalling, the most common side effect
2	Endometrial cancer	Tamoxifen acts as an oestrogenic agonist on the endometrium, stimulating endometrial cell proliferation and increasing the risk of endometrial carcinoma (especially with long-term use >5 years)
3	Venous thromboembolism (DVT/PE)	Tamoxifen's partial oestrogenic effect in the liver increases production of clotting factors and reduces protein S/antithrombin, promoting a prothrombotic state with risk of deep vein thrombosis and pulmonary embolism
4	Vaginal bleeding and discharge	Due to the endometrial oestrogenic agonist effect causing endometrial stimulation; also includes vaginal dryness in some patients and menstrual irregularities

(Other accepted adverse effects: cataracts/visual disturbances; nausea and vomiting; skin rash)

Summary Table

Part	Key Answer
Peau d'orange	Tumour blocks dermal lymphatics → lymphoedema → skin tethered at follicular openings → orange peel appearance
Enlarged axillary node	Tumour cells spread via lymphatics to axillary nodes → infiltration and enlargement
Fixation of lump	Desmoplastic reaction + invasion of Cooper's ligaments → fibrosis anchors tumour
IHC-Treatment	ER+/PR+ → Tamoxifen indicated; HER2- → Trastuzumab NOT indicated
IHC-Prognosis	ER+/PR+ = favourable (Luminal A); HER2- = better prognosis
Gene	BRCA1 (17q21) and BRCA2 (13q12.3) - TSGs for DNA double-strand break repair via homologous recombination; loss → genomic instability → cancer
Tamoxifen MOA	Competitive ER antagonist in breast → ER-tamoxifen complex recruits co-repressors → blocks oestrogen-driven gene transcription → inhibits tumour cell proliferation
Adverse effect 1	Hot flushes
Adverse effect 2	Endometrial cancer
Adverse effect 3	Venous thromboembolism
Adverse effect 4	Vaginal bleeding/discharge

This is a shared conversation. Sign in to Orris to start your own chat.